Correlation of Short Chain Fatty Acid Levels in Patients Non-Alcoholic Fatty Liver Disease with Obesity
), Zahra Safira(2), Rulli Rosandi(3), Supriono .(4), Bogi Pratomo Wibowo(5), Mark Muthiah(6),
(1) Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
(2) Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
(3) Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
(4) Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
(5) Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
(6) Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore
Corresponding Author
Abstract
Background: NAFLD has the potential to develop into severe diseases like NASH and cirrhosis and is often linked to obesity, although it can also occur in non-obese individuals, complicating diagnosis. SCFAs, produced by intestinal bacteria through the fermentation of dietary fibers, are essential for metabolic health and may influence liver fat and weight regulation. The purpose of this study was to explore the connection between SCFA levels and the severity of NAFLD, including liver fibrosis, in individuals both with and without obesity.
Methods: A cross-sectional investigation of 16 NAFLD patients with obesity and 11 without, with stool samples analyzed for SCFA via gas chromatography. Obesity was defined by abdominal circumference. Data were analyzed using Spearman’s correlation, Eta’s correlation, and Pearson’s test.
Results: Levels of SCFAs, including butyrate, propionate, and acetate, were significantly correlated in both obese and non-obese individuals diagnosed with NAFLD (r=0.618, p=0.001; p=0.019; p=0.037; p=0.012). Obesity was found to be positively associated with the severity of NAFLD (r=0.582, p=0.001). However, obesity did not exhibit a statistically significant connection with liver fibrosis (p = 0.351).
Conclusion: Obese NAFLD patients exhibited decreased SCFA levels compared to non-obese individuals. Central obesity was linked to NAFLD severity but not fibrosis progression. SCFAs and obesity are crucial in the pathogenesis of NAFLD.
Keywords: Central obesity, gut microbiota, NAFLD, SCFA
Keywords
References
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World journal of gastroenterology. 2018 Aug 8;24(30):3361. doi: 10.3748/wjg.v24.i30.3361.
Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & metabolic syndrome. 2020;12:1-20. doi:10.1186/s13098-020-00570-y.
Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocrine reviews. 2020 Feb;41(1):66-117.
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-1048. Available from: http://dx.doi.org/10.1016/j.metabol.2015.12.012.
Fachrureza M, Pratomo B. Lean Non-Alcoholic Fatty Liver Diasese (NAFLD). Clin Res J Intern Med. 2020;01(1):1–8. https://doi.org/10.21776/ub.crjim.2020.001.01.6
Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P, Geier A. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European gastroenterology journal. 2018 Dec;6(10):1496-1507. Available from: https://doi.org/10.1177/2050640618804
Nu'man AS, Akram NH, Hidayah N, Jayanti S, Handayani I, Massi MN. Gut microbiome profiling in nonalcoholic fatty liver disease and healthy individuals in Indonesian population. Journal of Medical Sciences. 2022 Jul 1;42(4):166-174.Available from: 10.4103/jmedsci.jmedsci_25_21
Pezzino S, Sofia M, Faletra G, Mazzone C, Litrico G, La Greca G, Latteri S. Gut–Liver axis and non-alcoholic fatty liver disease: A vicious circle of dysfunctions orchestrated by the gut microbiome. Biology. 2022 Nov 6;11(11):1622-1632. Available from: https://doi.org/10.3390/biology11111622
Lu Y, Yang H, Xu Z, Tang X. Association between different obesity patterns and the risk of developing type 2 diabetes mellitus among adults in eastern China: a cross-sectional study. Diabetes, Metabolic Syndrome and Obesity. 2021;14(1):2631-2639. Available from: https://doi.org/10.2147/DMSO.S309400
Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian journal of endocrinology and metabolism. 2013 Nov 1;17(6):990-995. Available from: 10.4103/2230-8210.122606
Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15(4):474–485. Available from: http://dx.doi.org/10.1016/j.cgh.2016.08 .028
Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19(4):359–366. Available from: https://doi.org/10.1016/j.aohep.2020.03.001
Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11(2):1–13. Available from: https://doi.org/10.15252/emmm.201809302
Shi J, Yang Z, Niu Y, Zhang W, Li X, Zhang H, et al. Large mid-upper arm circumference is associated with metabolic syndrome in middle-aged and elderly individuals: A community-based study. BMC Endocr Disord. 2020;20(1):1–8. Available from: https://doi.org/10.1186/s12902-020-00559-8
Wang X, Li X, Jin R, Yang J, Huang R, Wei L, et al. Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study. Hepatol Commun. 2022;6(9):2262–2272. Available from: DOI: 10.1002/hep4.1990
Lazarus J V., Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60–78. Available from: https://doi.org/10.1038/ s41575-021-00523-4
Kam LY, Huang DQ, Teng MLP, Takahashi H, Tanaka K, Yasuda S, et al. Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis. Dig Dis. 2022;40(6):734–744. Available from: https://doi.org/10.1159/000521662
Sun J, Yan C, Wen J, Wang F, Wu H, Xu F. Association between different obesity patterns and the risk of NAFLD detected by transient elastography: a cross-sectional study. BMC Gastroenterol [Internet]. 2024;24(1):1–10. Available from: https://doi.org/10.1186/s12876-024-03303-x
Najafi F, Pasdar Y, Nazar MM, Darbandi M. Association between obesity phenotypes and non-alcoholic fatty liver: a large population-based study. BMC Endocr Disord. 2024;24(1):1–11. Available from: https://doi.org/10.1186/s12902-024-01630-4
Cho HC. Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population. Gut Liver. 2016;10(1):117–125. Available from: 10.5009/gnl14444
Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: The Zhejiang Zhenhai study. Am J Gastroenterol [Internet]. 2013;108(8):1299–1304. Available from: http://dx.doi.org/10.1038/ajg.2013.104
Song Q, Zhang X. The Role of Gut – Liver Axis in Gut Microbiome Dysbiosis. Biomedicines [Internet]. 2022;10(524):1–14. Available from: https://doi.org/10.3390/ biomedicines10030524
Anand S, Mande SS. Host-microbiome interactions: Gut-Liver axis and its connection with other organs. npj Biofilms Microbiomes. 2022;8(1):89-99. Available from: https://doi.org/10.1038/s41522-022-00352-6
Kang GG, Trevaskis NL, Murphy AJ, Febbraio MA. Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH. Iscience. 2022;26(1):1059-1065. Available from: https://doi.org/10.1016/j.isci.2022.105905
Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol [Internet]. 2019;15(5):261–273. Available from: http://dx.doi.org/10.1038/s41574-019-0156-z
Mao Q, Lin B, Zhang W, Zhang Y, Zhang Y, Cao Q, Xu M. Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives. Frontiers in Pharmacology. 2024 Mar 21;15:137-157. Available from: https://doi.org/10.3389/fphar.2024.1371574
Vu V, Kim YM, Cho M. Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics. Appl Biol Chem [Internet]. 2023;66(1):1–15. Available from: https://doi.org/10.1186/s13765-022-00755-1.
Article Metrics
Abstract View
: 58 times
Download : 15 times
DOI: 10.24871/261202528-35
Refbacks
- There are currently no refbacks.
